0.74 USD
▲-0.01+1.73%
盘后 0.73 +0.14%
2026-08-03
市值
$160.93M
市盈率
—
EPS
-0.46
股息率
—
52 周区间
0.53 – 2.35
成交量
1.61M
Beta
2.84
目标价
3.20
52W 低 0.5352W 高 2.35
价格走势
公司简介
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection ...